A prognostic model for patients with primary extramedullary multiple myeloma

被引:2
|
作者
Zhang, Limei [1 ,2 ]
Chen, Shuzhao [1 ,2 ]
Wang, Weida [1 ,2 ]
Wang, Yun [1 ,2 ]
Liang, Yang [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Dept Hematol Oncol, State Key Lab Oncol South China, Guangzhou, Peoples R China
来源
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2022年 / 10卷
基金
中国国家自然科学基金;
关键词
extramedullary multiple myeloma; prognostic factors; overall survival; prognostic nomogram; progression-free survival; STEM-CELL TRANSPLANTATION; POOR-PROGNOSIS; DISEASE; NOMOGRAM; IMPACT; PLASMACYTOMAS; SURVIVAL; RELAPSES; OUTCOMES;
D O I
10.3389/fcell.2022.1021587
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: Extramedullary disease is a manifestation of multiple myeloma, the prognosis of which remains poor even in the era of novel drugs. Therefore, we aimed to develop a predictive model for patients with primary extramedullary multiple myeloma (EMM). Methods: Clinical and laboratory data of patients diagnosed with primary EMM between July 2007 and July 2021 were collected and analyzed. Univariate and least absolute shrinkage and selection operation Cox regression analyses (LASSO) were used to select prognostic factors for overall survival (OS) to establish a nomogram prognostic model. The performance of the model was evaluated using concordance index which was internally validated by bootstraps with 1,000 resample, area under the curve (AUCs), and calibration curves. Results: 217 patients were included in this retrospective study. Patients with EMM had a higher rate of belonging to the male sex, age >50 years, advanced Dude-Salmon stage III, hypercalcemia, and low hemoglobin level. Compared with patients with bone-related extramedullary disease, those with extraosseous-related extramedullary disease had a higher frequency of advanced Durie-Salmon stage III, lower rate of hypercalcemia, and elevated prothrombin time. The OS and progression-free survival (PFS) of patients with bone-related extramedullary disease were significantly higher than those of patients with extraosseous-related extramedullary disease. After the univariate and LASSO analyses, six prognostic factors, including performance status, number of extramedullary involved sites, beta 2-microglobulin, lactate dehydrogenase, monocyte-lymphocyte ratio, and prothrombin time, were integrated to establish a nomogram. The model showed robust discrimination with a concordance index (C-index) of 0.775 (95% confidence interval [CI], 0.713-0.836), internally validated with the corrected C-index of 0.756, and excellent performance in time-dependent AUCs compared with other staging systems. The AUCs for 1-, 3-, and 5-year OS were 0.814, 0.744, and 0.832, respectively. The calibration curves exhibited good consistency between the observed and nomogram-predicted OS. The 5-year OS of patients in the high-risk group (23.3%; 95% CI, 13.9%-39.3%) was much worse than that in the low-risk group (73.0%; 95% CI, 62.5%-85.4%; p < 0.001). Conclusion: The nomogram predictive model based on six clinical variables showed good prognostic performance and could better predict individual survival in patients with EMM.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Patients with extramedullary manifestation of multiple myeloma: Prognostic factors and survival.
    Wieczorek, Agnieszka Anna
    Balci, Derya
    Schmidt-Hieber, Martin
    Lohneis, Philipp
    Heider, Ulrike
    Pezzutto, Antonio
    Blau, Igor Wolfgang
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Prognostic impact of extramedullary plasmacytomas in multiple myeloma.
    Mattei, D
    Grasso, M
    Poggi, A
    Graziani, F
    Gallamini, A
    BLOOD, 2000, 96 (11) : 278B - 279B
  • [3] Prognostic Value of Inflammatory Factors in Extramedullary Multiple Myeloma
    Toth, Tunde
    Alizadeh, Hussain
    Polgar, Beata
    Kemeny, Agnes
    Faludi, Peter
    Reglodi, Dora
    Tamas, Andrea
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S568 - S569
  • [4] EXTRAMEDULLARY RELAPSES IN PATIENTS WITH MULTIPLE MYELOMA
    Papanikolaou, X.
    Maltezas, D.
    Repousis, P.
    Tzenou, T.
    Megalakaki, K.
    Sahanas, S.
    Agelopoulou, M.
    Vasilakopoulos, T.
    Mitsouli-Mentzikof, C.
    Pangalis, G.
    Panagiotidis, P.
    Kyrtsoni, M. -C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 617 - 617
  • [5] Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma
    He, JingSong
    Yue, XiaoYan
    He, DongHua
    Zhao, Yi
    Yang, Yang
    Zheng, GaoFeng
    Zhang, Enfan
    Han, XiaoYan
    Wu, WenJun
    Yang, Li
    Chen, Jing
    Cai, Zhen
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [6] Extramedullary multiple myeloma
    Bhutani, Manisha
    Foureau, David M.
    Atrash, Shebli
    Voorhees, Peter M.
    Usmani, Saad Z.
    LEUKEMIA, 2020, 34 (01) : 1 - 20
  • [7] Extramedullary multiple myeloma
    Weinstock, Matthew
    Ghobrial, Irene M.
    LEUKEMIA & LYMPHOMA, 2013, 54 (06) : 1135 - 1141
  • [8] Extramedullary multiple myeloma
    Manisha Bhutani
    David M. Foureau
    Shebli Atrash
    Peter M. Voorhees
    Saad Z. Usmani
    Leukemia, 2020, 34 : 1 - 20
  • [9] Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease
    Wang, Jing
    Shen, Na
    Shen, Xuxing
    Zhang, Run
    Jin, Yuanyuan
    Li, Jianyong
    Chen, Lijuan
    ANNALS OF MEDICINE, 2023, 55 (02)
  • [10] Survival Trends and Prognostic Factors of Patients with Newly Diagnosed Multiple Myeloma Accompanied with Extramedullary Disease
    Wang, Jing
    Shen, Na
    Shen, Xuxing
    Zhang, Run
    Jin, Yuan
    Li, Jianyong
    Chen, Lijuan
    BLOOD, 2023, 142